Trends in CNS Drug Discovery

Dario Doller earned a Ph.D. in Organic Chemistry from the Facultad de Ciencias Exactas y Naturales, UBA, Argentina. He conducted postdoctoral studies with Sir Derek Barton at Texas A&M University. His industrial career includes Rohm & Haas, Schering-Plough Research Institute, 3-Dimensional Pharmaceuticals, Gliatech, Neurogen, Lundbeck, CoNCERT, Sage, Sunovion Pharmaceuticals, Lucy Therapeutics, and iNeuro Therapeutics, where he is currently director of medicinal chemistry. He contributed to the discovery of the marketed PAR-1 antagonist vorapaxar and the clinical compounds NGD-4715, Lu AF09535, and CTP-692. He coauthored over 100 articles, patents or patent applications, and book chapters, and edited the book Allosterism in Drug Discovery. Current interests include molecular concepts at the chemistry/biology interface to enhance the translatability of preclinical research.